Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. Later that year, Doblin sued the DEA for the first time.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] 8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. Defining Psychedelics.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

NewsMunchies

NOVEMBER 12, 2021

In clinical trials, psilocybin (the psychoactive substance in mushrooms) has shown tremendous promise in treating severe depression, post-traumatic stress disorder, and other mental illnesses. As such, magic mushroom therapy offers hope. Additional clinical trials underway in the U.S. In a typical year in the U.S.

Clinical Trials 90

Clinical Trials Therapy Decriminalization DEA 90

Cannabis Law Report

MAY 31, 2022

Two approaches apply to commercial operations—the traditional medical path and the emerging non-medical state-regulated path, while the other two paths are better seen as non-commercial—underground therapy and religious use. 2022 Active FDA Clinical Trials and State-Regulated Systems. On March 5, 2019, the U.S.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. Psychedelic therapy is not a fringe phenomenon.

Law 105

Law Therapy Clinical Trials Research and Development 105

Canna Law Blog

MARCH 4, 2020

From 2015 to 2018, the number of clinics increased from 60 to 300; that number is undoubtedly higher today. People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. So, how does one lawfully open and operate a ketamine clinic for infusion therapy given the foregoing?

Therapy 90

Therapy Legalization Chronic Pain DEA 90

SpeedWeed

MARCH 28, 2021

CANNABIS CULTURE – The results are now in after the first-ever legal clinical trial into the use of cannabis to treat PTSD, but did the DEA’s rules taint the outcome? Seventy-six mostly male veterans between the ages of 24 and 77 completed the Phase 1 trial.

Clinical Trials 52

Clinical Trials DEA Treatment THC 52

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. Mitchell et al., Divito & Robert F. Johnson & Roland R. 11 × 11.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

APRIL 13, 2022

North American Industry Leader in Psychedelic Therapy and Research. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Shared mission of responsibly reintroducing psychedelic therapy to mental healthcare.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

OCTOBER 5, 2021

The drug has previously been used with some success in clinical trials designed to treat depression. These trials typically involve the use of music playlists to support the psychedelic experience. What we need to do now is optimise this approach probably through individualising and personalising music tracks in therapy.”.

Clinical Trials 52

Clinical Trials Research and Development DEA Therapy 52

Veriheal

APRIL 11, 2022

Drug Enforcement Agency (DEA). I look forward to a time when they are not considered alternative therapies or home remedies but actually first-line therapies,” said the CEO of Zelira, Oludare Odumosu. “We Groff confirmed that it had completed its first batch of medicinal-grade cannabis for research purposes on Feb.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

MedicalJane

JUNE 29, 2018

The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome. The Next Move Is On The DEA.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

DECEMBER 21, 2021

This UK-based company caught our attention in 2021 for its team of renowned psychedelic researchers, including chief research officer Professor David Nutt, chief medical officer Dr. Ben Sessa, and head of ketamine psychotherapy Dr. Celia Morgan, as well as its unique studies into ketamine treatment for addiction and gambling addiction.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

MARCH 2, 2020

Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to Compass Pathways ‘ psilocybin therapy for treatment-resistant depression. A few months later, the agency awarded BTD for Usona Institute ‘s psilocybin therapy for major depressive disorder. Then, something strange happened.

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

Canna Law Blog

MARCH 4, 2020

From 2015 to 2018, the number of clinics increased from 60 to 300; that number is undoubtedly higher today. People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. So, how does one lawfully open and operate a ketamine clinic for infusion therapy given the foregoing?

Legalization 52

Legalization Therapy Chronic Pain DEA 52

CannaMD

AUGUST 8, 2020

Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential. CBD Scheduling Rule Change. But the government is clear. What can CBD do?

CBD 99

CBD DEA Research and Development Hemp 99

Weedistry

MARCH 7, 2019

A team of Spanish scientists led by Manuel Guzman conducted the first clinical trial assessing the antitumoral action of THC on human beings. Guzman administered pure THC via a catheter into the tumors of nine hospitalized patients with glioblastoma, who had failed to respond to standard brain-cancer therapies.

THC 40

THC CBD Clinical Trials Research and Development 40

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Lancet Neurol Dec 23 2015.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73